Similar articles for PMID: 31659386

Year	Number of Results
2013	1
2014	2
2015	3
2016	10
2017	17
2018	11
2019	25
2020	26
2021	4
2024	0

1

Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?

Shankar-Hari M, Fish M, Azoulay E. Shankar-Hari M, et al. Intensive Care Med. 2020 Jan;46(1):119-121. doi: 10.1007/s00134-019-05814-8. Epub 2019 Oct 28. Intensive Care Med. 2020. PMID: 31659386 No abstract available.

2

Targeting Immune Cell Checkpoints during Sepsis.

Patil NK, Guo Y, Luan L, Sherwood ER. Patil NK, et al. Int J Mol Sci. 2017 Nov 14;18(11):2413. doi: 10.3390/ijms18112413. Int J Mol Sci. 2017. PMID: 29135922 Free PMC article. Review.

3

Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.

Koppolu V, Rekha Vasigala VK. Koppolu V, et al. J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175. doi: 10.4103/jcrt.JCRT_1290_16. J Cancer Res Ther. 2018. PMID: 30488824 Free article. Review.

4

Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.

Takahashi R, Sato Y, Kimishima M, Shiohara T, Ohyama M. Takahashi R, et al. Int J Clin Oncol. 2020 Oct;25(10):1861-1869. doi: 10.1007/s10147-020-01732-8. Epub 2020 Jul 12. Int J Clin Oncol. 2020. PMID: 32656742

5

New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.

Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J. Delasos L, et al. J Oncol Pharm Pract. 2021 Apr;27(3):716-721. doi: 10.1177/1078155220943949. Epub 2020 Jul 28. J Oncol Pharm Pract. 2021. PMID: 32723064 Review.

6

Nivolumab in renal cell carcinoma.

Michel Ortega RM, Drabkin HA. Michel Ortega RM, et al. Expert Opin Biol Ther. 2015 Jul;15(7):1049-60. doi: 10.1517/14712598.2015.1049596. Epub 2015 Jun 3. Expert Opin Biol Ther. 2015. PMID: 26038957 Review.

7

Development of Cancer Immunotherapy Targeting the PD-1 Pathway.

Kamimura N, Wolf AM, Iwai Y. Kamimura N, et al. J Nippon Med Sch. 2019;86(1):10-14. doi: 10.1272/jnms.JNMS.2019_86-2. J Nippon Med Sch. 2019. PMID: 30918149 Free article. Review.

8

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Riaz N, et al. Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12. Cell. 2017. PMID: 29033130 Free PMC article.

9

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.

Tsai HF, Hsu PN. Tsai HF, et al. J Biomed Sci. 2017 May 25;24(1):35. doi: 10.1186/s12929-017-0341-0. J Biomed Sci. 2017. PMID: 28545567 Free PMC article. Review.

10

CD4⁺ T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade.

Fu J, Yu A, Xiao X, Tang J, Zu X, Chen W, He B. Fu J, et al. Am J Cancer Res. 2020 Dec 1;10(12):4234-4250. eCollection 2020. Am J Cancer Res. 2020. PMID: 33414997 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

88 results

Results by year